Ideaya Shares Rise After First Patient Enrolled in Combination Trial for MTAP-Deleted Tumors
Ideaya Biosciences shares climbed in morning trading after the company announced the first patient enrollment in a Phase 1/2 study testing the combination of IDE892 (PRMT5 inhibitor) and IDE397 (MAT2A inhibitor) in MTAP-deleted solid tumors, including non-small cell lung cancer and pancreatic cancer. The milestone, targeted publicly for mid-2026, s…